Founded in 2017 by Dr. Martin Schiller of the University of Nevada, Heligenics Inc. was established to realize the promise of the functional genome and precision medicine.
"Heli" is derived from “hǣlan” an old English word that means “to heal” and “genics” which stands for genomics
Heligenics was converted to a C corporation in late 2019. We started with just two employees and a team of advisors. We now have 8 research and administration employees, 8 sales consultants, and 3 board members. We have successfully closed some deals and are now seeking new customers and partners for this year production queue.
Heligenics recently moved from our startup building to a class A research facility within the Roseman University Summerlin Campus.
To prevent disease and heal patients afflicted with illness through genomics.
Based on the GigaAssay technology developed at the University of Nevada Las Vegas in the Schiller Laboratory of Applied Bioinformatics, our GigaAssay is a massively parallel biological platform that can simultaneously measure how tens of thousands of genetic variants or other sequence variables affect a molecular function or a cell process. To date, there are no other established high-throughput assays that assess biological function.
The GigaAssay produces functional genomics data that can be licensed and used for prevention-based approaches, diagnostics, drug selection and discovery of new biologic drugs. Additionally, for developing new drug therapies or redesigning clinical trials for drugs that have failed a trial due to poor efficacy or safety. Heligenics products will transform the medical industry.